SCHEMBL29601694

SCHEMBL29601694

O=C(NCC(F)(F)F)c1ccnc(Nc2nc(-c3ccccn3)cs2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN1 Q92952 2/20 0.56
KCNN2 Q9H2S1 2/20 0.56
KCNN3 Q9UGI6 2/20 0.56
SLC2A1 P11166 1/20 0.55
MECP2 P51608 1/20 0.55
MBD2 Q9UBB5 1/20 0.55
ADORA3 P0DMS8 6/20 0.51
KDM4A O75164 3/20 0.51
KDM4B O94953 3/20 0.51
KDM5B Q9UGL1 3/20 0.51
CSNK2A2 P19784 1/20 0.51
CSNK2B P67870 1/20 0.51
CSNK2A1 P68400 1/20 0.50
GRM1 Q13255 1/20 0.49
NPY5R Q15761 1/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
KDM5C P41229 1/20 0.47
MAPT P10636 4/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24358255 1.00 KCNN1 (0.56) KCNN1KCNN2KCNN3SLC2A1MECP2
SCHEMBL27039795 0.87 KCNN1 (0.62) KCNN1KCNN2KCNN3SLC2A1MECP2
SCHEMBL27039778 0.86 KCNN1 (0.58) KCNN1KCNN2KCNN3SLC2A1MECP2
SCHEMBL27039871 0.83 KCNN1 (0.55) KCNN1KCNN2KCNN3SLC2A1MECP2
SCHEMBL30745737 0.83 KCNN1 (0.58) KCNN1KCNN2KCNN3SLC2A1MECP2
SCHEMBL24358256 0.83 KCNN1 (0.58) KCNN1KCNN2KCNN3SLC2A1MECP2
SCHEMBL29601353 0.82 CSNK2A2 (0.73) KCNN1KCNN2KCNN3SLC2A1MECP2
SCHEMBL29078754 0.82 CSNK2A2 (0.73) KCNN1KCNN2KCNN3SLC2A1MECP2
SCHEMBL29078737 0.82 KCNN1 (0.58) KCNN1KCNN2KCNN3SLC2A1MECP2
SCHEMBL24358064 0.82 GABRA5 (0.45) KCNN1KCNN2KCNN3SLC2A1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025891-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES CELGENE CORPORATION 2024-01-25 US disclosed
EP-4232449-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES Celgene Corporation (US) 2023-08-30 EP disclosed
WO-2022087326-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES CELGENE CORPORATION (US) 2022-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025891-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES CYP8B1, PAH, INHA KCNN1 4605/4885KCNN2 4592/4885KCNN3 4470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.